Close

Raymond James Downgrades Acadia Pharmaceuticals (ACAD) to Outperform

Go back to Raymond James Downgrades Acadia Pharmaceuticals (ACAD) to Outperform

Form 8-K ACADIA PHARMACEUTICALS For: Mar 08

March 8, 2021 4:30 PM EST

Exhibit 99.1

Acadia Pharmaceuticals Provides Regulatory Update on

Supplemental New Drug Application for Pimavanserin for the Treatment of

Hallucinations and Delusions Associated with Dementia-Related Psychosis... More